Daily interferon Alpha-2B and ribavirin combination therapy for liver transplant patients with chronic hepatitis C infection☆
To access this article, please choose from the options below
☆ This work was supported by Essex Pharma GmbH, München, Germany.
PII: S0041-1345(03)00681-X
doi:10.1016/S0041-1345(03)00681-X
© 2003 Elsevier Science Inc. All rights reserved.
